Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.
The Oligonucleotide Synthesis Market was valued at USD 4.26 Billion in 2024, and is expected to reach USD 8.97 Billion by 2030, rising at a CAGR of 13.21%
This market plays a vital role in advancing biopharmaceutical innovation, serving as a cornerstone for applications such as gene editing, molecular diagnostics, and RNA-based therapies. The sector's rapid expansion is closely tied to breakthroughs in genomics and personalized medicine, where demand for high-fidelity, tailor-made oligonucleotides has soared.
As pharmaceutical companies and research institutions increasingly focus on RNA therapeutics and gene-targeting treatments, the need for scalable and precise oligonucleotide production continues to intensify. Clinical trials - particularly in North America and Europe - underscore the broadening scope of oligonucleotide-based treatments. With robust investments, growing biotech collaborations, and the evolution of synthesis technologies, the market is positioned for sustained innovation and global adoption.
RNA-Based Therapeutics
RNA-based therapeutics have emerged as a powerful tool for treating a wide range of diseases, propelling the demand for synthetic oligonucleotides. Applications like small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies rely on precise nucleotide synthesis.
The global spotlight on mRNA vaccines - particularly those developed for COVID-19 - has significantly increased awareness and investment in this segment. Beyond vaccines, RNA-based therapeutics are targeting chronic conditions and rare genetic disorders by altering or silencing specific gene expressions. These therapies require advanced oligonucleotide sequences manufactured with stringent quality and precision standards, highlighting the growing dependence on oligonucleotide synthesis for modern drug development pipelines.
Efficiency and Scalability
Despite strong demand, the industry faces persistent challenges in scaling up oligonucleotide production without compromising quality. High-throughput synthesis processes require consistent optimization to maintain cost-effectiveness, especially as research moves from lab-scale to commercial-scale applications.
Additionally, synthesizing complex, longer, or chemically modified oligonucleotides can be resource-intensive, requiring specialized equipment and infrastructure. Compliance with global regulatory standards adds another layer of complexity, necessitating rigorous quality controls. These hurdles can increase production timelines and costs, potentially slowing down commercialization, especially for startups and smaller biopharma companies.
Therapeutic Advancements
Therapeutic innovation remains a defining trend in the oligonucleotide synthesis market. The success of mRNA vaccines has validated RNA-based platforms, sparking a surge in R&D investments aimed at tackling conditions like cancer, neurodegenerative diseases, and rare genetic disorders. Oligonucleotides are central to these developments, forming the basis for antisense therapies, RNA interference (RNAi), and gene-editing technologies such as CRISPR.
This growing reliance on synthetic nucleic acids has intensified efforts to develop faster, purer, and more cost-efficient synthesis technologies. As pharmaceutical pipelines increasingly include nucleic acid-based drugs, demand for specialized synthesis services and materials is expected to rise significantly, solidifying the sector's strategic importance in modern medicine.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 182 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $4.26 Billion |
| Forecasted Market Value (USD) by 2030 | $8.97 Billion |
| Compound Annual Growth Rate | 13.2% |
| Regions Covered | Global |
Report Scope
Key Market Players
- Thermo Fisher Scientific Inc
- Agilent Technologies, Inc.
- Merck KGaA
- BIO-Synthesis Inc
- Eurofins Scientific SE
- Danaher Corporation
- Ajinomoto Bio-Pharma Services
- Biogen Inc.
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc
Oligonucleotide Synthesis Market, By Product Type:
- Synthesized Oligonucleotide Products
- Reagents
- Equipment
- Services
Oligonucleotide Synthesis Market, By Application:
- Research
- Therapeutics
- Diagnostics
Oligonucleotide Synthesis Market, By End User:
- Academic Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospital & Diagnostic Laboratories
Oligonucleotide Synthesis Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
For more information about this report visit https://www.researchandmarkets.com/r/fdwklg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
